Merryn Voysey

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti, Katie Ewer, Parvinder K. Aley et al. · The Lancet · 2020 · 2.6K citations · Full text

Vaccination, Vaccine Safety, Phase 1/2 +7

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

Shabir A. Madhi, Vicky L. Baillie, Clare Cutland et al. · New England Journal of Medicine · 2021 · 1.3K citations · Full text

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Shuo Feng, Daniel J. Phillips, Thomas White et al. · Nature Medicine · 2021 · 1.2K citations · Full text

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Wanwisa Dejnirattisai, Jiandong Huo, Daming Zhou et al. · Cell · 2022 · 1K citations · Full text

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Katherine R. W. Emary, Tanya Golubchik, Parvinder K. Aley et al. · The Lancet · 2021 · 649 citations · Full text